New MASH Treatment Research Will Be Presented In Denver
Researchers will discuss new insights into the investigational drug lanifibranor for patients with liver disease.
Updated on Oct. 6, 2026 in Asthma
Live Poll
Do you trust that current pharmaceutical research is effectively leading to better treatments for chronic diseases?
Inventiva will present three scientific abstracts on the drug candidate lanifibranor at the AASLD The Liver Meeting in Denver from November 5 to 9, 2026. These presentations focus on the biological rationale for using this pan-PPAR approach to treat metabolic dysfunction-associated steatohepatitis (MASH).
Why it matters
These abstracts aim to provide translational insights into how targeting PPAR isoforms simultaneously may address the complex drivers of MASH. The findings could further clarify the therapeutic potential of this approach as the drug undergoes Phase 3 testing.
Preclinical and Phase 2b data showed that lanifibranor improved liver sinusoidal endothelial cell alterations, and plasma cell-free DNA analysis identified epigenetic changes in the PPAR family. These findings remain preliminary as they are being presented ahead of expected NATiV3 Phase 3 results.
The players
Inventiva
A clinical-stage biopharmaceutical company focused on the development of therapies for non-alcoholic steatohepatitis and other metabolic diseases.
AASLD
The American Association for the Study of Liver Diseases is a professional organization dedicated to preventing and curing liver disease.
The details
Lanifibranor is an investigational medicine that works by activating PPARα, PPARδ, and PPARγ isoforms to regulate gene expression in the liver. By simultaneously engaging these receptors, the drug aims to counteract the metabolic and inflammatory processes that drive MASH pathophysiology. The upcoming presentations will detail this mechanism, including evidence of epigenetic modifications associated with PPAR pathway changes.
Timeline
November 5, 2026: The conference begins and the first abstract is presented.
November 7, 2026: The second and third abstracts are presented to attendees.
November 9, 2026: The conference concludes in Denver.
Q4 2026: Topline results from the Phase 3 NATiV3 clinical trial are expected.
Health Landscape
This research contributes to the evolving landscape of MASH treatment by investigating a pan-PPAR approach to address liver disease. It specifically complements the ongoing NATiV3 Phase 3 clinical trial, which remains the definitive test for this drug's clinical utility.
As lanifibranor is currently an investigational medicine not approved by any regulatory authority, it is not available for patient use. If you have been diagnosed with MASH, it is worth discussing the current status of emerging therapies and your overall treatment plan with your doctor.
The takeaway
The study of PPAR isoforms represents a complex but promising area of research for addressing liver disease drivers. Residents should monitor for updates from the NATiV3 trial in late 2026 to understand whether this investigational approach will eventually become a standard treatment option.
What happens next
Topline results from the NATiV3 clinical trial for MASH are expected to be released in the fourth quarter of 2026.
Further reading
For more information on the latest research and clinical standards, visit Asthma.
Live Poll
Do you trust that current pharmaceutical research is effectively leading to better treatments for chronic diseases?
